Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells

Cancer Research

Volumn 59, Issue 6, 1999, Pages 1244-1251

  Cover, Carolyn M ^a   Hsieh, S Jean ^a   Cram, Erin J ^a   Hong, Chibo ^a   Riby, Jacques E ^a   Bjeldanes, Leonard F ^a   Firestone, Gary L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLEMETHANOL; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BRASSICA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VEGETABLE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CDC2-CDC28 KINASES; CELL CYCLE; CELL DIVISION; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASES; ESTROGEN ANTAGONISTS; HUMANS; INDOLES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RETINOBLASTOMA PROTEIN; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0033559197     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Loub, W. D., Wattenberg, L. W., and Davis, D. W. Aryl hydrocarbon hydroxylase induction in rat tissues by naturally occurring indoles of cruciferous plants. J. Natl. Cancer Inst. (Bethesda), 54: 985-988, 1975.
2. Wattenberg, L. W., and Loub, W. D. Inhibition of polycyclic aromatic hydrocarbon-induced neoplasia by naturally occurring indoles. Cancer Res., 38: 1410-1413, 1978.
3. Morse, M. A., LaGreca, S. D., Amin, S. G., and Chung, F. L. Effects of indole-3-carbinol on lung tumorigenesis and DNA methylation induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and on the metabolism and disposition of NNK in A/J mice. Cancer Res., 50: 2613-2617, 1990.
4. Bradlow, H. L., Michnovicz, J., Telang, N. T., and Osborne, M. P. Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis (Lond.), 12: 1571-1574, 1991.
5. Bjeldanes, L. F., Kim, J. Y., Grose, K. R., Bartholomew, J. C., and Bradfield, C. A. Aromatic hydrocarbon responsiveness-receptor agonists generated from indole-3-carbinol in vitro and in vivo: comparisons with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Proc. Natl. Acad. Sci. USA, 88: 9543-9547, 1991.
6. 1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J. Biol. Chem., 273: 3838-3847, 1998.
7. Pennisi, E. Drug's link to genes reveals estrogen's many sides. Science (Washington DC), 273: 1171, 1996.
8. Powles, T. J. Efficacy of tamoxifen as treatment of breast cancer. Semin. Oncol., 24 (Suppl. 1): S1-48-S1-54, 1997.
9. Forbes, J. F. The control of breast cancer: the role of tamoxifen. Semin. Oncol., 24 (Suppl. 1): S1-5-S1-19, 1997.
10. Skidmore, J. R., Walpole, A. L., and Woodburn, J. Effect of some triphenylethylenes on oestradiol binding in vitro to macromolecules from uterus and anterior pituitary. J. Endocrinol., 52: 289-298, 1972.
11. 3H] tamoxifen in rat uterine cytosols. A comparison of swinging bucket and vertical tube rotor sucrose density gradient analysis. Mol. Cell. Endocrinol., 8: 179-188, 1977.
12. Gallo, M. A., and Kaufman, D. Antagonistic and agonistic effects of tamoxifen: significance in human cancer. Semin. Oncol., 24 (Suppl. 1): S1-71-S1-80, 1997.
13. Tsai, L. C., Hung, M. W., Yuan, C. C., Chao, P. L., Jiang, S. Y., Chang, G. G., and Chang, T. C. Effects of tamoxifen and retinoic acid on cell growth and c-myc gene expression in human breast and cervical cancer cells. Anticancer Res., 17: 4557-4562, 1997.
14. Lindner, D. J., Kolla, V., Kalvakolanu, D. V., and Borden, E. C. Tamoxifen enhances interferon-regulated gene expression in breast cancer cells. Mol. Cell. Biochem., 167: 169-177, 1997.
15. Otto, A. M., Paddenberg, R., Schubert, S., and Mannherz, H. G. Cell-cycle arrest, micronucleus formation, and cell death in growth inhibition of MCF-7 breast cancer cells by tamoxifen and cisplatin. J. Cancer Res. Clin. Oncol., 122: 603-612, 1996.
16. Hamel, P. A., and Hanley, H. J. G1 cyclins and control of the cell division cycle in normal and transformed cells. Cancer Invest., 15: 143-152, 1997.
17. Musgrove, E. A., Swarbrick, A., Lee, C. S. L., Cornish, A. L., and Sutherland, R. L. Mechanisms of cyclin-dependent kinase inactivation by progestins. Mol. Cell. Biol., 18: 1812-1825, 1998.
18. 1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J. Biol. Chem., 272: 10882-10894, 1997.
19. Hunter, T., and Pines, J. Cyclins and cancer. II: cyclin D and CDK inhibitors come of age. Cell, 79: 573-582, 1994.
20. Morgan, D. O. Principles of CDK regulation. Nature (Lond.), 374: 131-134, 1995.
21. Sherr, C. J., and Roberts, J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev., 9: 1149-1163, 1995.
22. Sherr, C. J. Cancer cell cycles. Science (Washington DC), 274: 1672-1677, 1996.
23. Hirai, H., Roussel, M. F., Kato, J. Y., Ashmun, R. A., and Sherr, C. J. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol. Cell. Biol., 15: 2672-2681, 1995.
24. Reynisdottir, I., and Massague, J. The subcellular locations of p15(lnk4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev., 11: 492-503, 1997.
25. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701-704, 1993.
26. Alessandrini, A., Chiaur, D. S., and Pagano, M. Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia (Baltimore), 11: 342-345, 1997.
27. Slansky, J. E., and Farnham, P. J. Introduction to the E2F family: protein structure and gene regulation. Curr. Top. Microbiol. Immunol., 208: 1-30, 1996.
28. Santell, R. C., Chang, Y. C., Nair, M. G., and Helferich, W. G. Dietary genistein exerts estrogenic effects upon the uterus, mammary gland and the bypothalamic/ pituitary axis in rats. J. Nutr., 127: 263-269, 1997.
29. Bardon, S., Vignon, F., Derocq, D., and Rochefort, H. The antiproliferative effect of tamoxifen in breast cancer cells: mediation by the estrogen receptor. Mol. Cell. Endocrinol., 35: 89-96, 1984.
30. Draetta, G. F. Mammalian G1 cyclins. Curr. Opin. Cell. Biol., 6: 842-846, 1994.
31. Van heusden, J., Wouters, W., Ramaekers, F. C., Krekels, M. D., Dillen, L., Borgers, M. and Smets, G. The antiproliferative activity of all-trans-retinoic acid catabolites and isomers is differentially modulated by liarozole-fumarate in MCF-7 human breast cancer cells. Br. J. Cancer, 77: 1229-1235, 1998.
32. Planas, S. M., and Weinberg, R. A. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol. Cell. Biol., 17: 4059-4069, 1997.
33. Morgan, D. O. The dynamics of cyclin dependent kinase structure. Curr. Opin. Cell Biol., 8: 767-77, 1996.
34. Smigel, K. Breast Cancer Prevention Trial shows major benefit, some risk. J. Natl. Cancer Inst. (Bethesda), 90: 647-648, 1998.
35. Legha, S. S. Tamoxifen in the treatment of breast cancer. Ann. Intern. Med., 109: 219-228, 1988.
36. Couillard, S., Gutman, M., Labrie, C., Belanger, A., Candas, B., and Labrie, F. Comparison of the effects of the antiestrogens EM-800 and tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice. Cancer Res., 58: 60-64, 1998.
37. Gottardis, M. M., and Jordan, V. C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res., 48: 5183-5187, 1988.
38. Osborne, C. K., Coronado-Heinsohn, E. B., Hilsenbeck, S. G., McCue, B. L., Wakeling, A. E., McClelland, R. A., Manning, D. L., and Nicholson, R. I. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J. Natl. Cancer Inst. (Bethesda), 87: 746-750, 1995.
39. Wiebe, V. J., Osborne, C. K., Fuqua, S. A., and DeGregorio, M. W. Tamoxifen resistance in breast cancer. Crit. Rev. Oncol. Hematol., 14: 173-188, 1993.
40. Lykkesfeldt, A. E. Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer. Acta Oncol., 35 (Suppl. 5): 9-14, 1996.
41. Baldwin, W. S., and LeBlanc, G. A. The anti-carcinogenic plant compound indole-3-carbinol differentially modulates P450-mediated steroid hydroxylase activities in mice. Chem. Biol. Interact., 83: 155-169, 1992.
42. Bradfield, C. A., and Bjeldanes, L. F. Effect of dietary indole-3-carbinol on intestinal and hepatic monooxygenase, glutathione 5-transferase and epoxide hydrolase activities in the rat. Food Chem. Toxicol., 22: 977-982, 1984.
43. McDanell, R., McLean, A. E., Hanley, A. B., Heaney, R. K., and Fenwick, G. R. The effect of feeding Brassica vegetables and intact glucosinolates on mixed-function-oxidase activity in the livers and intestines of rats. Food Chem. Toxicol., 27: 289-293, 1989.
44. Michnovicz, J. J., and Bradlow, H. L. Induction of estradiol metabolism by dietary indole-3-carbinol in humans. J. Natl. Cancer Inst. (Bethesda), 82: 947-949, 1990.
45. Bradlow, H. L., Michnovicz, J. J., Halper, M., Miller, D. G., Wong, G. Y., and Osborne, M. P. Long-term responses of women to indole-3-carbinol or a high fiber diet. Cancer Epidemiol. Biomark. Prev., 3: 591-595, 1994.